vs
吉利德科学（GILD）与Ross Stores（ROST）财务数据对比。点击上方公司名可切换其他公司
吉利德科学的季度营收约是Ross Stores的1.4倍（$7.9B vs $5.6B），吉利德科学净利率更高（27.5% vs 9.1%，领先18.4%），Ross Stores同比增速更快（10.4% vs 4.7%），吉利德科学自由现金流更多（$3.1B vs $617.8M），过去两年吉利德科学的营收复合增速更高（8.9% vs -3.6%）
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
Ross Stores, Inc.是美国知名折扣百货连锁集团，旗下核心品牌为Ross Dress for Less，总部位于加利福尼亚州都柏林，是美国规模最大的平价零售商。截至2024年7月，集团在全美43个州、华盛顿特区、波多黎各及关岛共运营1795家门店，暂未覆盖新英格兰地区及阿拉斯加，另拥有门店数超353家的折扣零售品牌DD's Discounts。
GILD vs ROST — 直观对比
营收规模更大
GILD
是对方的1.4倍
$5.6B
营收增速更快
ROST
高出5.7%
4.7%
净利率更高
GILD
高出18.4%
9.1%
自由现金流更多
GILD
多$2.5B
$617.8M
两年增速更快
GILD
近两年复合增速
-3.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $7.9B | $5.6B |
| 净利润 | $2.2B | $511.9M |
| 毛利率 | 79.5% | 28.0% |
| 营业利润率 | 25.0% | 11.6% |
| 净利率 | 27.5% | 9.1% |
| 营收同比 | 4.7% | 10.4% |
| 净利润同比 | 22.4% | 4.7% |
| 每股收益（稀释后） | $1.75 | $1.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GILDROST
| Q4 25 | $7.9B | $5.6B | ||
| Q3 25 | $7.8B | $5.5B | ||
| Q2 25 | $7.1B | $5.0B | ||
| Q1 25 | $6.7B | $5.9B | ||
| Q4 24 | $7.6B | $5.1B | ||
| Q3 24 | $7.5B | $5.3B | ||
| Q2 24 | $7.0B | $4.9B | ||
| Q1 24 | $6.7B | $6.0B |
净利润GILDROST
| Q4 25 | $2.2B | $511.9M | ||
| Q3 25 | $3.1B | $508.0M | ||
| Q2 25 | $2.0B | $479.2M | ||
| Q1 25 | $1.3B | $586.8M | ||
| Q4 24 | $1.8B | $488.8M | ||
| Q3 24 | $1.3B | $527.1M | ||
| Q2 24 | $1.6B | $488.0M | ||
| Q1 24 | $-4.2B | $609.7M |
毛利率GILDROST
| Q4 25 | 79.5% | 28.0% | ||
| Q3 25 | 79.8% | 27.6% | ||
| Q2 25 | 78.8% | 28.2% | ||
| Q1 25 | 76.9% | 26.5% | ||
| Q4 24 | 79.1% | 28.3% | ||
| Q3 24 | 79.1% | 28.3% | ||
| Q2 24 | 77.8% | 28.1% | ||
| Q1 24 | 76.8% | 27.3% |
营业利润率GILDROST
| Q4 25 | 25.0% | 11.6% | ||
| Q3 25 | 42.8% | 11.5% | ||
| Q2 25 | 34.9% | 12.2% | ||
| Q1 25 | 33.6% | 12.4% | ||
| Q4 24 | 32.4% | 11.9% | ||
| Q3 24 | 11.8% | 12.5% | ||
| Q2 24 | 38.0% | 12.2% | ||
| Q1 24 | -64.6% | 13.2% |
净利率GILDROST
| Q4 25 | 27.5% | 9.1% | ||
| Q3 25 | 39.3% | 9.2% | ||
| Q2 25 | 27.7% | 9.6% | ||
| Q1 25 | 19.7% | 9.9% | ||
| Q4 24 | 23.6% | 9.6% | ||
| Q3 24 | 16.6% | 10.0% | ||
| Q2 24 | 23.2% | 10.0% | ||
| Q1 24 | -62.4% | 10.1% |
每股收益（稀释后）GILDROST
| Q4 25 | $1.75 | $1.58 | ||
| Q3 25 | $2.43 | $1.56 | ||
| Q2 25 | $1.56 | $1.47 | ||
| Q1 25 | $1.04 | $1.79 | ||
| Q4 24 | $1.43 | $1.48 | ||
| Q3 24 | $1.00 | $1.59 | ||
| Q2 24 | $1.29 | $1.46 | ||
| Q1 24 | $-3.34 | $1.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.0M | $4.1B |
| 总债务越低越好 | $24.9B | $1.5B |
| 股东权益账面价值 | $22.7B | $5.9B |
| 总资产 | $59.0B | $15.4B |
| 负债/权益比越低杠杆越低 | 1.10× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资GILDROST
| Q4 25 | $68.0M | $4.1B | ||
| Q3 25 | $19.0M | $3.8B | ||
| Q2 25 | $69.0M | $3.8B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | — | $4.3B | ||
| Q3 24 | — | $4.7B | ||
| Q2 24 | — | $4.7B | ||
| Q1 24 | — | $4.9B |
总债务GILDROST
| Q4 25 | $24.9B | $1.5B | ||
| Q3 25 | $24.9B | $1.5B | ||
| Q2 25 | $24.9B | $1.5B | ||
| Q1 25 | $25.0B | $2.2B | ||
| Q4 24 | $26.7B | $2.2B | ||
| Q3 24 | $23.2B | $2.5B | ||
| Q2 24 | $23.3B | $2.5B | ||
| Q1 24 | $25.2B | $2.5B |
股东权益GILDROST
| Q4 25 | $22.7B | $5.9B | ||
| Q3 25 | $21.5B | $5.7B | ||
| Q2 25 | $19.7B | $5.6B | ||
| Q1 25 | $19.2B | $5.5B | ||
| Q4 24 | $19.3B | $5.3B | ||
| Q3 24 | $18.5B | $5.1B | ||
| Q2 24 | $18.3B | $4.9B | ||
| Q1 24 | $17.5B | $4.9B |
总资产GILDROST
| Q4 25 | $59.0B | $15.4B | ||
| Q3 25 | $58.5B | $14.5B | ||
| Q2 25 | $55.7B | $14.3B | ||
| Q1 25 | $56.4B | $14.9B | ||
| Q4 24 | $59.0B | $14.9B | ||
| Q3 24 | $54.5B | $14.7B | ||
| Q2 24 | $53.6B | $14.5B | ||
| Q1 24 | $56.3B | $14.3B |
负债/权益比GILDROST
| Q4 25 | 1.10× | 0.26× | ||
| Q3 25 | 1.16× | 0.26× | ||
| Q2 25 | 1.27× | 0.27× | ||
| Q1 25 | 1.30× | 0.40× | ||
| Q4 24 | 1.38× | 0.42× | ||
| Q3 24 | 1.26× | 0.48× | ||
| Q2 24 | 1.28× | 0.50× | ||
| Q1 24 | 1.44× | 0.51× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $3.1B | $617.8M |
| 自由现金流率自由现金流/营收 | 39.4% | 11.0% |
| 资本支出强度资本支出/营收 | 2.6% | 3.7% |
| 现金转化率经营现金流/净利润 | 1.52× | 1.62× |
| 过去12个月自由现金流最近4个季度 | $9.5B | $2.0B |
8季度趋势，按日历期对齐
经营现金流GILDROST
| Q4 25 | $3.3B | $827.1M | ||
| Q3 25 | $4.1B | $668.4M | ||
| Q2 25 | $827.0M | $409.7M | ||
| Q1 25 | $1.8B | $882.6M | ||
| Q4 24 | $3.0B | $513.4M | ||
| Q3 24 | $4.3B | $592.1M | ||
| Q2 24 | $1.3B | $368.9M | ||
| Q1 24 | $2.2B | $948.8M |
自由现金流GILDROST
| Q4 25 | $3.1B | $617.8M | ||
| Q3 25 | $4.0B | $466.6M | ||
| Q2 25 | $720.0M | $202.3M | ||
| Q1 25 | $1.7B | $676.6M | ||
| Q4 24 | $2.8B | $333.0M | ||
| Q3 24 | $4.2B | $394.6M | ||
| Q2 24 | $1.2B | $232.7M | ||
| Q1 24 | $2.1B | $726.4M |
自由现金流率GILDROST
| Q4 25 | 39.4% | 11.0% | ||
| Q3 25 | 51.0% | 8.4% | ||
| Q2 25 | 10.2% | 4.1% | ||
| Q1 25 | 24.8% | 11.4% | ||
| Q4 24 | 37.4% | 6.6% | ||
| Q3 24 | 55.2% | 7.5% | ||
| Q2 24 | 17.2% | 4.8% | ||
| Q1 24 | 31.6% | 12.1% |
资本支出强度GILDROST
| Q4 25 | 2.6% | 3.7% | ||
| Q3 25 | 1.9% | 3.6% | ||
| Q2 25 | 1.5% | 4.2% | ||
| Q1 25 | 1.6% | 3.5% | ||
| Q4 24 | 1.9% | 3.6% | ||
| Q3 24 | 1.9% | 3.7% | ||
| Q2 24 | 1.9% | 2.8% | ||
| Q1 24 | 1.6% | 3.7% |
现金转化率GILDROST
| Q4 25 | 1.52× | 1.62× | ||
| Q3 25 | 1.35× | 1.32× | ||
| Q2 25 | 0.42× | 0.85× | ||
| Q1 25 | 1.34× | 1.50× | ||
| Q4 24 | 1.67× | 1.05× | ||
| Q3 24 | 3.44× | 1.12× | ||
| Q2 24 | 0.82× | 0.76× | ||
| Q1 24 | — | 1.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
ROST
暂无分部数据
